{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:30:49Z","timestamp":1791077449140,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Danish Agency for Science, Technology and Innovation (Det Strategiske Forskningsr\u00e5d)","award":["09-065746"],"award-info":[{"award-number":["09-065746"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jconrel.2013.05.030","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T15:35:33Z","timestamp":1370360133000},"page":"167-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100"],"prefix":"10.1016","volume":"170","author":[{"given":"Islam","family":"Hamad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Christy","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Moein","family":"Moghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2013.05.030_bb0005","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s11095-006-9104-4","article-title":"A review of poloxamer 407 pharmaceutical and pharmacological characteristics","volume":"23","author":"Dumortier","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1107\/S0021889899013369","article-title":"Formation of homogeneous gel-like phases by mixed triblock copolymer micelles in aqueous solution: FCC to BCC phase transition","volume":"33","author":"Liu","year":"2000","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0167-7799(00)01485-2","article-title":"Poloxamers and poloxamines in nanoparticle engineering and experimental medicine","volume":"18","author":"Moghimi","year":"2000","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0142-9612(89)90103-8","article-title":"Diffusion of rat atrial natriuretic factor in thermoreversible poloxamer gels","volume":"10","author":"Juhasz","year":"1989","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(99)00307-5","article-title":"Controlled release of vancomycin from poloxamer 407 gels","volume":"192","author":"Veyries","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-3659(00)00215-7","article-title":"Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution, drug release in stirred systems","volume":"67","author":"Moore","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0035","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ejcts.2006.02.024","article-title":"Effects of purified poloxamer 407 gel on vascular occlusion and the coronary endothelium","volume":"29","author":"Boodhwani","year":"2006","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0040","first-page":"48","article-title":"Poloxamer 407 as an intraperitoneal barrier material for the prevention of postsurgical adhesion formation and reformation in rodent models for reproductive surgery","volume":"77","author":"Steinleitner","year":"1991","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0045","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.biomaterials.2003.10.085","article-title":"Temporary vascular occlusion with poloxamer 407","volume":"25","author":"Raymond","year":"2004","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbadis.2004.02.005","article-title":"Causative factors behind poloxamer 188 (Pluronic F68, Flocor\u2122)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels","volume":"1689","author":"Moghimi","year":"2004","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0055","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1021\/nn101990a","article-title":"Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere\u2013serum interface: implications for stealth nanoparticle engineering","volume":"4","author":"Hamad","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.molimm.2008.08.276","article-title":"Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process","volume":"46","author":"Hamad","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0065","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1021\/nn3055175","article-title":"Single-walled carbon nanotube surface control of complement recognition and activation","volume":"7","author":"Andersen","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0070","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and hemostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2010.04.003","article-title":"Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead","volume":"146","author":"Moghimi","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0080","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.addr.2011.06.002","article-title":"Material properties in complement activation","volume":"63","author":"Moghimi","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0085","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0090","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.addr.2012.05.010","article-title":"Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward","volume":"64","author":"Moghimi","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/0962935031000134860","article-title":"Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages","volume":"12","author":"Johnston","year":"2003","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08982100600848801","article-title":"Activation of the human complement system by cholesterol-rich and PEGylated liposomes\u2014modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels","volume":"16","author":"Moghimi","year":"2006","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s102380200004","article-title":"Relationship between serum complement and different lipid disorders","volume":"2","author":"Pasqui","year":"2002","journal-title":"Clin. Exp. Med"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0110","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI26206","article-title":"Shotgun proteomics implicate protease inhibition and complement activation in the anti-inflammatory properties in HDL","volume":"117","author":"Vaisar","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2012.08.029","article-title":"Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients","volume":"225","author":"Parra","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ab.2006.11.028","article-title":"Modification of the Stewart biphasic colorimetric assay for stable and accurate quantitative determination of Pluronic and Tetronic block copolymers for application in biological systems","volume":"361","author":"Al-Hanbali","year":"2007","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0130","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1096\/fj.06-6186fje","article-title":"Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production","volume":"20","author":"Moghimi","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1084\/jem.148.1.207","article-title":"Human C4-binding protein. I. Isolation and characterization","volume":"148","author":"Scharfstein","year":"1978","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0168-3659(02)00009-3","article-title":"Pluronic\u00ae block copolymers as novel polymer therapeutics for drug and gene delivery","volume":"82","author":"Kabanov","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0145","first-page":"40","article-title":"Preparation and characterization of spironolactone solid dispersions using hydrophilic carriers","volume":"7","author":"Shah","year":"2012","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0150","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1016\/S0021-9258(18)33952-8","article-title":"Ultrastructure of cobra venom factor-dependent C3\/C5 convertase and its zymogen, factor B of human complement","volume":"257","author":"Smith CA","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0155","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1567-5769(01)00006-6","article-title":"Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions","volume":"1","author":"Szebeni","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","article-title":"Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective","volume":"52","author":"Moghimi","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0165","doi-asserted-by":"crossref","first-page":"8454","DOI":"10.1021\/nn2038252","article-title":"Reshaping the future of nanopharmaceuticals: ad iudicium","volume":"5","author":"Moghimi","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0170","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.4049\/jimmunol.133.6.3167","article-title":"The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers","volume":"133","author":"Hunter","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0175","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V59.6.1299.1299","article-title":"Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis","volume":"59","author":"Vercellotti","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0180","first-page":"192","article-title":"Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injections to rats","volume":"46","author":"Wout","year":"1992","journal-title":"J. Parenter. Sci. Technol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0185","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0006-2952(93)90668-M","article-title":"Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat","volume":"46","author":"Johnston","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0021-9150(97)00193-7","article-title":"Poloxamer 407-induced atherogenesis in the C57BL\/6 mouse","volume":"136","author":"Palmer","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0195","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.molimm.2006.06.013","article-title":"Modified low density lipoproteins differently bind and activate C1 complex of complement","volume":"44","author":"Biro","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0200","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1016\/S0021-9258(18)53740-6","article-title":"Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9","volume":"268","author":"Hamilton","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0205","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI115504","article-title":"The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells","volume":"88","author":"Hamilton","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0079-6107(03)00028-2","article-title":"On the structure and function of apolipoproteins: more than a family of lipid-binding proteins","volume":"83","author":"Bolanos-Garcia","year":"2003","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0215","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nri800","article-title":"Evolution of lectin\u2013complement pathway and its role in innate immunity","volume":"2","author":"Fujita","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/CS20080106","article-title":"High-density lipoproteins, inflammation and oxidative stress","volume":"116","author":"Tabet","year":"2009","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0225","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1021\/bi962895r","article-title":"Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization","volume":"36","author":"McDonald","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2013.05.030_bb0230","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.4049\/jimmunol.151.4.2159","article-title":"Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9","volume":"151","author":"Tschopp","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0065-3233(08)60641-5","article-title":"Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins","volume":"45","author":"Schumaker","year":"1994","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0240","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0022-2275(20)30267-4","article-title":"Structure of apolipoprotein B-100 in low density lipoproteins","volume":"42","author":"Segrest","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2013.05.030_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(87)90088-8","article-title":"Apolipoprotein B: structure, biosynthesis and role in lipoprotein assembly process","volume":"68","author":"Olofsson","year":"1987","journal-title":"Atherosclerosis"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913003209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913003209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T05:51:12Z","timestamp":1688277072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365913003209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0168365913003209"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.030","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}